Search for dissertations about: "kinase activity"
Showing result 21 - 25 of 580 swedish dissertations containing the words kinase activity.
-
21. Structure determination of Methanocaldococcus jannaschii nucleoside kinase
Abstract : All organisms can be divided into the tree kingdoms of life: Archaea, Bacteria and Eukarya. Archaeal organisms are often found to exhibit, compared to human perspectives, extreme environments, such as high temperature, high salt and acidic habitats. Many archaeal species are hyperthermophiles, i.e. READ MORE
-
22. AMP-activated protein kinase in adipose tissue
Abstract : The AMP-activated protein kinase (AMPK) is a ubiquitously expressed kinase, which is activated in response to depletion of cellularenergy levels. Once active, it functions to alter cellular metabolism in a way that leads to restoration of energy levels. Therefore,AMPK is described as the key regulator of cellular energy homeostasis. READ MORE
-
23. DNA-dependent protein kinase in human cells
Abstract : DNA-dependent protein kinase (DNA-PK) is a holoenzyme consisting of a regulatory subunit, the heterodimeric Ku70/86, and a catalytic subunit known as DNA-dependent protein kinase catalytic subunit (DNA-PKcs). DNA-PK takes part in a number of cellular functions including growth control, immunoglobulin gene rearrangement and DNA repair. READ MORE
-
24. Protein kinase C epsilon and neurite outgrowth
Abstract : Protein kinase C (PKC) is a serine/threonine kinase family with 10 identified isoforms. The contribution of PKC isoforms to cell growth and differentiation, with focus on neurite outgrowth, was investigated, using neuroblastoma and immortalised neural cells as model systems. READ MORE
-
25. Aspects on long-term treatment with tyrosine kinase inhibitors in Chronic myeloid leukemia
Abstract : Chronic myeloid leukemia (CML) is caused by the tyrosine kinase activity of the oncoprotein BCR-ABL. The introduction of tyrosine kinase inhibitors (TKIs) targeting BCR-ABL has profoundly changed the prognosis of CML. Currently, there are three TKIs approved for treatment of CML, imatinib, nilotinib and dasatinib. READ MORE